Gene Therapy May Aid Duchenne Muscular Dystrophy Care
A systematic review found that children with Duchenne muscular dystrophy showed functional improvements after gene therapy treatment.
Updated on Oct. 26, 2026 in Children’s Health
Live Poll
Do you trust emerging gene therapies to effectively treat rare diseases in pediatric patients?
A systematic review of 107 pediatric patients with Duchenne muscular dystrophy indicates that the gene therapy delandistrogene moxeparvovec may improve physical function and muscle protein levels. The findings, collected at a 12-month follow-up, suggest potential benefits for children living with this progressive condition.
Why it matters
Duchenne muscular dystrophy currently lacks treatments that provide more than short-term benefit for patients. This research offers insight into how gene therapy may help preserve physical function and address the underlying biological causes of the disease.
This systematic review of four studies evaluated 300 participants, including 107 patients with Duchenne muscular dystrophy, at 12 months post-treatment. While the therapy showed improvements in functional scores and dystrophin content, long-term randomized controlled trial results are still required.
The details
Delandistrogene moxeparvovec functions as a gene therapy designed to increase the production of dystrophin, a critical protein missing in patients with Duchenne muscular dystrophy. By delivering a functional gene to muscle cells, the treatment aims to restore structural integrity and slow the progression of muscle weakness. The study noted significant improvements in functional tests, including the North Star Ambulatory Assessment, time-to-rise scores, and the 10-meter walk/run test.
Timeline
Data collection for the treatment cohort occurred at a 12-month follow-up.
Health Landscape
The search for effective gene therapies represents a major shift in the treatment arc for Duchenne muscular dystrophy, moving from symptom management toward addressing the genetic root of the condition. This study updates the efficacy figures associated with the development pipeline for Duchenne muscular dystrophy gene therapies.
Families and patients navigating Duchenne muscular dystrophy may find these results useful to discuss with a neuromuscular specialist. It is important to review current clinical options with a physician to understand how new therapies fit into a comprehensive care plan.
The takeaway
Gene therapy continues to show promise in modifying the progression of Duchenne muscular dystrophy by increasing dystrophin production. Families should monitor clinical trial registries and consult with specialists regarding ongoing advancements in therapeutic options.
Further reading
For more on evolving research, visit our Children’s Health section.
Source note: This article includes information reported by Derm Immuno Today.
Live Poll
Do you trust emerging gene therapies to effectively treat rare diseases in pediatric patients?
